Shanghai Shyndec Pharmaceutical Co (600420) Fair Value & Analysis

Healthcare · CN · Market cap 11.7B CNY

A solid business, currently priced close to our fair value.

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• Our model range runs from ¥6.75 (bear) to ¥11.25 (bull), base ¥9.00. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 64/100 (solid quality) with medium evidence: read the verdict with care.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.

How to read this chart

60‑month range ¥7.78 – ¥14.17 · fair‑value band ¥6.75 – ¥11.25 · the ¥8.70 price screens below the ¥9.00 fair value. Dashed = 300-day average. As of Aug 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Shanghai Shyndec Pharmaceutical Co (600420) currently trades at ¥8.70, while our model-based Fair Value estimate is ¥9.00, implying the stock looks roughly 3.5% fairly valued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Shanghai Shyndec Pharmaceutical Co generated revenue of 8.8B CNY at a net margin of 8.2%. Revenue declined 20.8% year over year. It earns a return on equity of 5.7%. The balance sheet holds a net cash position of 5.1B CNY. Fundamentals as of Aug 9, 2026

Our scenario range runs from ¥6.75 (bear case) to ¥11.25 (bull case); at ¥8.70, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 3%, 600420 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥22.66) versus Dividend Discount (¥5.14). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China.

Full company description

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granules, and cefdinir dispersible tablets. It also offers nifedipine controlled-release tablets, amlodipine besylate tablets, enalapril maleate tablet, pravastatin sodium tablets, olmesartan medoxomil hydrochlorothiazide tablets, olmesartan amlodipine tablets; milnaprom hydrochloride tablets, lofen codeine tablets, gastrodin injection, naloxone hydrochloride injection, piracetam injection; and apmis film, tacrolimus capsules, mannan peptide for injection, imatinib mesylate. In addition, the company provides methylprednisolone sodium succinate for injection, octreotide acetate injection, betamethasone sodium phosphate for injection, dexamethasone sodium phosphate injection; diclofenac sodium sustained release tablets; 6-aminopenicillinic acid, azithromycin, amoxicillin, potassium clavulanate microcrystalline cellulose, ceftriaxone sodium crude salt, 7-aminocephalosporanic acid, chorionic gonadotropin, urinary gonadotropin; and naphazoline hydrochloride nasal drops, Ambroxol Hydrochloride Oral Solution. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 1996 and is based in Shanghai, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Shanghai Shyndec Pharmaceutical Co reported revenue of ¥9.4B in FY2025 versus ¥13.9B in FY2021, a compound −9.5%/yr. Reported net income was ¥944M in FY2025, compounding +13.5%/yr from FY2021.

Watch 600420: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.